Decoy Therapeutics Inc. Cost of Revenue
Decoy Therapeutics Inc. (DCOY) reported Cost of Revenue of $36.15 thousand for the 3-month period ending 2019-06-30, per its 10-Q filed 2019-07-17.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2019-07-17
- Decoy Therapeutics Inc. cost of goods and services sold for the quarter ending 2019-06-30 was $36.15K, a 79.91% decline year-over-year.
- Decoy Therapeutics Inc. cost of goods and services sold for the quarter ending 2019-03-31 was $47.33K, a 43.61% decline year-over-year.
- Decoy Therapeutics Inc. cost of goods and services sold for the quarter ending 2018-12-31 was $74.93K, a 43.80% decline year-over-year.
- Decoy Therapeutics Inc. cost of goods and services sold for the quarter ending 2018-09-30 was $91.94K, a 38.20% decline year-over-year.
- Decoy Therapeutics Inc. cost of goods and services sold for fiscal 2018 was $430.75K, a 14.96% decline from fiscal 2017.
- Decoy Therapeutics Inc. cost of goods and services sold for fiscal 2017 was $506.53K, a 23.57% decline from fiscal 2016.
- Decoy Therapeutics Inc. cost of goods and services sold for fiscal 2016 was $662.75K.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2019-06-30 | $36.15K 10-Q · filed 2019-07-17 | $83.48K 10-Q · filed 2019-07-17 | $158.41K derived: sum of 3 quarters · filed 2019-07-17 | $250.35K derived: sum of 4 quarters · filed 2019-07-17 |
| 2019-03-31 | $47.33K 10-Q · filed 2019-05-01 | $122.26K derived: sum of 2 quarters · filed 2019-05-01 | $214.20K derived: sum of 3 quarters · filed 2019-05-01 | $394.14K derived: sum of 4 quarters · filed 2019-07-17 |
| 2018-12-31 | $74.93K 10-K · filed 2019-03-06 | $166.87K derived: sum of 2 quarters · filed 2019-03-06 | $346.82K derived: sum of 3 quarters · filed 2019-07-17 | $430.75K 10-K · filed 2019-03-06 |
| 2018-09-30 | $91.94K 10-K · filed 2019-03-06 | $271.88K derived: sum of 2 quarters · filed 2019-07-17 | $355.82K 10-Q · filed 2018-11-05 | $489.16K derived: sum of 4 quarters · filed 2019-07-17 |
| 2018-06-30 | $179.94K 10-Q · filed 2019-07-17 | $263.88K 10-Q · filed 2019-07-17 | $397.22K derived: sum of 3 quarters · filed 2019-07-17 | $545.98K derived: sum of 4 quarters · filed 2019-07-17 |
| 2018-03-31 | $83.93K 10-Q · filed 2019-05-01 | $217.28K derived: sum of 2 quarters · filed 2019-05-01 | $366.03K derived: sum of 3 quarters · filed 2019-05-01 | $511.36K derived: sum of 4 quarters · filed 2019-05-01 |
| 2017-12-31 | $133.34K 10-K · filed 2019-03-06 | $282.10K derived: sum of 2 quarters · filed 2019-03-06 | $427.42K derived: sum of 3 quarters · filed 2019-03-06 | $506.53K 10-K · filed 2019-03-06 |
| 2017-09-30 | $148.76K 10-K · filed 2019-03-06 | $294.08K derived: sum of 2 quarters · filed 2019-03-06 | $373.19K 10-Q · filed 2018-11-05 | |
| 2017-06-30 | $145.32K 10-K · filed 2019-03-06 | $224.43K 10-Q · filed 2018-08-01 | ||
| 2017-03-31 | $79.11K 10-K · filed 2019-03-06 | |||
| 2016-12-31 | $662.75K 10-K · filed 2019-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |